Zimbabwe’s NAC Boosts Lifesaving Kidney Care for People Living with HIV
By Michael Gwarisa In a landmark move, the National AIDS Council (NAC) has stepped in to support Zimbabwe’s growing renal care burden, particularly for People Living with HIV (PLHIV), by funding essential dialysis services at Parirenyatwa Hospital. The intervention comes amid growing concern about the hidden epidemic of kidney failure among people on lifelong antiretroviral
Read More“I’ll Fix It”: Elon Musk Responds to Outcry Over Lenacapavir Funding Halt
By Michael Gwarisa Billionaire Elon Musk, who also serves as an advisor to United States President Donald Trump, has hinted at intervening in the ongoing funding crisis affecting global HIV programs—particularly the rollout of Lenacapavir, a groundbreaking once-a-year HIV prevention drug. Musk made the remarks during a conversation with Bloomberg’s Mitchell Hussein at the Qatar
Read MoreBotswana Achieves Gold Tier Status in Eliminating Mother-to-Child Transmission of HIV
By Staff Reporter Botswana has achieved gold tier status in its efforts to eliminate mother-to-child transmission (MTCT) of HIV. The country received this recognition during the plenary session of the Seventy-eighth World Health Assembly, awarded by the Director-General of the World Health Organization (WHO). In 2021, Botswana became the first country in the world to
Read MoreDr. Nyaradzo Mgodi Honored for Leadership in Landmark HIV Vaccine Study
By Michael Gwarisa Dr. Nyaradzo Mgodi, a renowned Zimbabwean clinician-researcher and the Site Leader for the University of Zimbabwe Clinical Trials Research Centre (UZ-CTRC) in Zengeza, has been awarded the prestigious HIV Vaccine Trials Network (HVTN) Service Award for her outstanding leadership and contribution to the groundbreaking Antibody Mediated Prevention (AMP) study. The award was
Read MoreZim Has Enough ARVs to Last Through 2025, Says Health Minister Mombeshora
By Kuda Pembere Zimbabwe has enough antiretroviral (ARV) drugs to last through the end of 2025, Health and Child Care Minister Douglas Mombeshora said Friday, allaying public concerns over a looming shortage. Speaking to HealthTimes, Mombeshora assured the nation that the country has an eight-month supply of adult ARVs, sufficient to meet the needs of
Read MoreGlobal Fund Procures African-Made First-Line HIV Treatment
By HealthTimes Reporter The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has reached a historic milestone by procuring – for the first time – a first-line HIV treatment manufactured in Africa. The treatment – lifesaving, quality-assured antiretroviral medicines (ARVs) called TLD (tenofovir, lamivudine and dolutegravir), prequalified by the World Health Organization
Read MoreMultimorbidity in Zimbabwe: A Wake-Up Call for Health System Reform
By Michael Gwarisa A landmark ethnographic study has raised urgent questions about Zimbabwe’s capacity to manage rising rates of multimorbidity, a growing health challenge defined as the coexistence of two or more chronic conditions in a single individual. Conducted by a multidisciplinary team of researchers from Zimbabwe and the United Kingdom, the study explores how
Read MoreZimbabwe to Begin HIV Vaccine Clinical Trial in May
By Kuda Pembere A clinical research study to assess the safety and efficacy of a new HIV vaccine is set to begin in Zimbabwe in May this year. The study will be coordinated across three sites: Mutala in Zimbabwe, the Desmond Tutu Health Foundation in Cape Town, and the Africa Health Research Institute in Durban.
Read MorePSH Adopts Social Enterprise Model to Sustain Health Services
By Michael Gwarisa In a strategic move to ensure long-term sustainability, Population Solutions for Health (PSH) is transforming part of its operations into income-generating ventures, positioning itself as a hybrid social enterprise amid waning international donor support. The shift comes at a time when global health programs are facing disruptions due to the withdrawal of
Read More
Future of ZIMPHIA Survey Uncertain as US Freezes Research Support
By Michael Gwarisa Zimbabwe’s prospects of conducting its third Population-based HIV Impact Assessment (ZIMPHIA), a crucial household-based national HIV survey, are hanging in the balance amid indications of potential funding cuts from the United States to global scientific research initiatives. Zimbabwe has already hosted two ZIMPHIA surveys—the first in 2015/2016 and the second in 2020.
Read More